ADMS News and Press, Adamas Pharmaceuticals Inc. From 02/13/20

EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVR...

Adamas Pharmaceuticals (NASDAQ: ADMS ) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at least two years. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Gainers: ADMS   +14.9% . SALT   +7.7% . MGI   +3.6% . ADMA   +3.5% . AKAM   +3.2% . More news on: Adamas Pharmaceuticals, Inc., Scorpio Bulkers Inc., MoneyGram International, Inc., Stocks on the move, , , News on ETFs Read more ...

-  Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease - Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF time sustained for at least two years EMERYVILLE, Calif., Feb. 11, 202...

New York, New York--(Newsfile Corp. - January 27, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) of the February 10, 2020 deadline to seek the role of lead plaintiff in a fed...

5 Penny Stocks On Robinhood To Watch This Month Investing in penny stock can often prove to be the most rewarding class of stocks for investors. Why? Over the years, these stocks have generated a lot of wealth for investors, quickly. One of the most important things that need to be pointed o...

Gainers: ShiftPixy (NASDAQ: PIXY ) +162% . More news on: ShiftPixy, Inc., Wah Fu Education Group Limited, Verastem, Inc., Stocks on the move, Read more ...

On a preliminary basis , Adamas Pharmaceuticals ( ADMS +10.3% ) expects Gocovri (amantadine) sales in Q4 and 2019 to be ~$16.3M (+23%) and ~$54.6M (+61%), respectively. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth quarter 2019 and approximately 25,780 for full year 2019 -- EMERYVILLE, Calif., Jan. 08...

EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a ...